Cargando…

Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia

Background: Small dense LDL-cholesterol is a recently discovered cardiovascular risk factor beyond LDL-cholesterol. Pemafibrate is a novel selective peroxisome proliferator-activated receptor-α modulator that reduces triglyceride levels. Given the significant association between triglycerides and sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hida, Yuki, Imamura, Teruhiko, Kinugawa, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648094/ https://www.ncbi.nlm.nih.gov/pubmed/37959379 http://dx.doi.org/10.3390/jcm12216915

Ejemplares similares

Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Prognostic Implication of Small Dense LDL-Cholesterol Levels following Acute Coronary Syndrome
por: Imamura, Teruhiko, et al.
Publicado: (2023)

Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events
por: Izumida, Toshihide, et al.
Publicado: (2022)

No change in small low‐density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial
por: Hirano, Tsutomu
Publicado: (2023)

Triglyceride and Small Dense LDL-Cholesterol in Patients with Acute Coronary Syndrome
por: Hori, Masakazu, et al.
Publicado: (2021)

Fatty liver in men is associated with high serum levels of small, dense low-density lipoprotein cholesterol
por: Hosoyamada, Kaori, et al.
Publicado: (2012)

Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies
por: Jin, Xiao, et al.
Publicado: (2022)

Constipation as a Drug-Related Adverse Effect in Patients with Hyperkalemia: Sodium Zirconium Cyclosilicate versus Conventional Potassium Binders
por: Hida, Yuki, et al.
Publicado: (2023)

The influence of triglycerides on small dense low‐density lipoprotein cholesterol levels is attenuated in low low‐density lipoprotein‐cholesterol range: Implications for the negative results of the PROMINENT trial
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Small Dense Low-Density Lipoprotein Cholesterol Levels in Breakfast Skippers and Staple Foods Skippers
por: Arimoto, Masako, et al.
Publicado: (2023)

Small Dense Low-Density Lipoprotein Cholesterol and Carotid Intimal Medial Thickness Progression
por: Ikezaki, Hiroaki, et al.
Publicado: (2020)

Association of Small Dense Low-Density Lipoprotein Cholesterol with Stroke Risk, Severity and Prognosis
por: Zhou, Peiyang, et al.
Publicado: (2020)

Small Dense Low‐Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study
por: Ikezaki, Hiroaki, et al.
Publicado: (2021)

Consuming High-Fat and Low-Fat Ground Beef Depresses High-Density and Low-Density Lipoprotein Cholesterol Concentrations, and Reduces Small, Dense Low-Density Lipoprotein Particle Abundance
por: Lytle, Jason R., et al.
Publicado: (2023)

Pulmonary Artery Pulsatility Index and Hemolysis during Impella-Incorporated Mechanical Circulatory Support
por: Nakamura, Makiko, et al.
Publicado: (2022)

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Serum concentrations of small dense low‐density lipoprotein cholesterol and lipoprotein(a) are related to coronary arteriostenosis in Takayasu arteritis
por: Chen, Si, et al.
Publicado: (2021)

Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes
por: Bando, Hidenori, et al.
Publicado: (2021)

Small Dense Low-Density Lipoprotein Cholesterol and the Risk of Coronary Heart Disease in a Japanese Community
por: Higashioka, Mayu, et al.
Publicado: (2020)

Correlation between small and dense low‐density lipoprotein cholesterol and cardiovascular events in Beijing community population
por: Wang, Xiaona, et al.
Publicado: (2021)

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Association between measured or calculated small dense low‐density lipoprotein cholesterol and oxidized low‐density lipoprotein in subjects with or without type 2 diabetes mellitus
por: Kim, Hyun‐Ki, et al.
Publicado: (2022)

Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus
por: Bando, Yukihiro, et al.
Publicado: (2016)

Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases
por: Ivanova, Ekaterina A., et al.
Publicado: (2017)

Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients
por: Shen, Hao, et al.
Publicado: (2016)

Small-Dense Low-Density Lipoprotein Cholesterol: A Subclinical Marker for the Primary Prevention of Coronary Heart Disease
por: Kokubo, Yoshihiro, et al.
Publicado: (2020)

The Association of Small Dense Low-Density Lipoprotein Cholesterol and Coronary Heart Disease in Subjects at High Cardiovascular Risk
por: Higashioka, Mayu, et al.
Publicado: (2021)

Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease
por: Ishii, Junnichi, et al.
Publicado: (2022)

Utilization of Small Dense Low-Density Lipoprotein Cholesterol Testing in Korean Patients Visiting Local Clinics and Hospitals
por: Choi, Rihwa, et al.
Publicado: (2022)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Correlation between of small dense low‐density lipoprotein cholesterol with acute cerebral infarction and carotid atherosclerotic plaque stability
por: QiaoZhen, Xue, et al.
Publicado: (2019)

Association between carotid intima media thickness and small dense low-density lipoprotein cholesterol in acute ischaemic stroke
por: Zhou, Peiyang, et al.
Publicado: (2020)

Predictive value of small dense low-density lipoprotein cholesterol for cardiovascular events in Chinese elder diabetes mellitus patients
por: Xu, Li, et al.
Publicado: (2021)

Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients
por: Nakayama, Atsuko, et al.
Publicado: (2022)

Small Dense Low-Density Lipoprotein Level in Newly Diagnosed Type 2 Diabetes Mellitus Patients With Normal Low-Density Lipoprotein
por: Juhi, Ayesha, et al.
Publicado: (2023)

Why are Skipping Breakfast and Skipping Staple Foods Inappropriate Dietary Patterns? The Association with Small Dense Low-Density Lipoprotein Cholesterol Levels
por: Kubota, Yoshimi
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d9emhhj6pm07olngduhn8n7anq